News

Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination

The drug regulator said that an additional clinical trial would be required to establish the efficacy of the protein restoration therapy ataluren for the rare and fatal genetic

PKU is an inborn error of metabolism (IEM) caused by a mutation in the gene that breaks down the amino acid phenylalanine (Phe). Phe accumulation in the blood

The data demonstrate that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic

Under the deal, the companies will study a portfolio of antibody targets, of which AbbVie will have global development and commercial rights to two targets. Alector has developed

The acquisition will add to Clinigen’s existing footprint in the country following the launch of its Japanese business in October 2016. The acquisition of IMMC is part of

The company has taken the decision based on three proof-of-concept studies, which does not show clinically meaningful efficacy results. The studies comprised of Phase 1 study in healthy

Tafinlar in combination with Mekinist is in development to become the first adjuvant treatment specifically for melanoma patients with a BRAF V600 mutation. The designation is based on

Both existing and new investors, including Auven Therapeutics, Redmile, the Wild Family Office and AstraZeneca oversubscribed and supported the financing. ADCT develops antibody drug conjugates (ADCs) that target